Literature DB >> 21682550

Trends in endometrial cancer incidence rates in the United States, 1999-2006.

Linh M Duong1, Reda J Wilson, Umed A Ajani, Simple D Singh, Christie R Eheman.   

Abstract

BACKGROUND: Risk factors for endometrial cancer, such as hormone replacement therapy (HRT) and obesity, have changed significantly in the last decade. We investigated trends in endometrial cancer histologic subtypes on a national level during 1999-2006.
METHODS: Data covering 88% of the U.S. population were from central cancer registries in the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) programs that met high-quality United States Cancer Statistics (USCS) criteria. Our analyses included females with microscopically confirmed invasive uterine cancer (n=257,039). Age-adjusted incidence rates and trends for all invasive uterine cancers and by endometrial cancer histologic subtypes (type I and II) were assessed.
RESULTS: There were 145,922 cases of type I endometrial cancers and 15,591 cases of type II for 1999-2006. We found that type I endometrial cancers have been increasing, whereas type II endometrial cancers and all invasive uterine cancers have been relatively stable throughout the 1999-2006 period.
CONCLUSIONS: During the past decade, the overall burden of uterine cancer has been stable, although there have been changes in underlying histologies (e.g., endometrial). Changes in trends for underlying histologies may be masked when reviewing trends irrespective of histologic subtypes. Our findings suggest the need to examine trends of uterine cancer by histologic subtype in order to better understand the burden of endometrial cancer in relation to these subtypes to help women at increased risk for developing more aggressive types of endometrial cancer (e.g., type II).

Entities:  

Mesh:

Year:  2011        PMID: 21682550     DOI: 10.1089/jwh.2010.2529

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  32 in total

Review 1.  Current status of molecular biomarkers in endometrial cancer.

Authors:  H M J Werner; H B Salvesen
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

2.  Traces of intact paraben molecules in endometrial carcinoma.

Authors:  Selen Dogan; Timur Tongur; Taner Erkaymaz; Gulgun Erdogan; Betul Unal; Bulent Sik; Tayup Simsek
Journal:  Environ Sci Pollut Res Int       Date:  2019-08-28       Impact factor: 4.223

3.  Sleep, quality of life, and depression in endometrial cancer survivors with obesity seeking weight loss.

Authors:  Nora L Nock; Anastasia Dimitropoulos; Kristine M Zanotti; Steven Waggoner; Christa Nagel; Mladen Golubic; Chad M Michener; John P Kirwan; Jay Alberts
Journal:  Support Care Cancer       Date:  2019-09-02       Impact factor: 3.603

4.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25

5.  Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Kari L Ring; Molly Daniels; Bryan M Fellman; Diana L Urbauer; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-13

6.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Authors:  Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino
Journal:  Gynecol Oncol       Date:  2013-02-26       Impact factor: 5.482

Review 7.  Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States.

Authors:  B Long; F W Liu; R E Bristow
Journal:  Gynecol Oncol       Date:  2013-05-23       Impact factor: 5.482

8.  Recent changes in endometrial cancer trends among menopausal-age U.S. women.

Authors:  Paige Wartko; Mark E Sherman; Hannah P Yang; Ashley S Felix; Louise A Brinton; Britton Trabert
Journal:  Cancer Epidemiol       Date:  2013-04-13       Impact factor: 2.984

9.  Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

Authors:  Brent J Tierney; Georgia A McCann; Shan Naidu; Kellie S Rath; Uksha Saini; Ross Wanner; Periannan Kuppusamy; Adrian Suarez; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2014-07-16       Impact factor: 5.482

10.  Cancer incidence trends among Asian American populations in the United States, 1990-2008.

Authors:  Scarlett Lin Gomez; Anne-Michelle Noone; Daphne Y Lichtensztajn; Steve Scoppa; James T Gibson; Lihua Liu; Cyllene Morris; Sandy Kwong; Kari Fish; Lynne R Wilkens; Marc T Goodman; Dennis Deapen; Barry A Miller
Journal:  J Natl Cancer Inst       Date:  2013-07-22       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.